With 0.72 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.35 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.41 whereas the lowest price it dropped to was $1.3. The 52-week range on RDHL shows that it touched its highest point at $6.80 and its lowest point at $0.90 during that stretch. It currently has a 1-year price target of $1000.00. Beta for the stock currently stands at 4.91.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RDHL was up-trending over the past week, with a rise of 25.69%, but this was up by 14.17% over a month. Three-month performance dropped to -31.16% while six-month performance fell -34.67%. The stock gained 33.01% in the past year, while it has lost -78.59% so far this year.
Float and Shares Shorts:
At present, 5.09 million RDHL shares are outstanding with a float of 4.53 million shares on hand for trading. On 2025-12-15, short shares totaled 76298.0, which was 229.0 higher than short shares on 1763078400. In addition to Mr. Dror Ben-Asher as the firm’s Co-Founder, Chairman & CEO, Mr. Razi Ingber serves as its Chief Financial Officer.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$40 being high and -$40 being low. For RDHL, this leads to a yearly average estimate of -$40. The surprise factor in the prior quarter was -$10.
